title: Scaling-up recombinant plasmid DNA for clinical trial: current concern, solution and status.
abstract: Gene therapy and vaccines are rapidly developing field in which recombinant nucleic acids are introduced in mammalian cells for enhancement, restoration, initiation or silencing biochemical function. Beside simplicity in manipulation and rapid manufacture process, plasmid DNA-based vaccines have inherent features that make them promising vaccine candidates in a variety of diseases. This present review focuses on the safety concern of the genetic elements of plasmid such as propagation and expression units as well as their host genome for the production of recombinant plasmid DNA. The highlighted issues will be beneficial in characterizing and manufacturing plasmid DNA for save clinical use. Manipulation of regulatory units of plasmid will have impact towards addressing the safety concerns raised in human vaccine applications. The gene revolution with plasmid DNA by alteration of their plasmid and production host genetics will be promising for safe delivery and obtaining efficient outcomes.
authors.affiliation: Laboratory of Immunotherapeutic and Vaccines, Institute of Bioscience, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia.
authors.forename: Ruzila
authors.initials: R
authors.lastname: Ismail
authors.forename: Zeenathul Nazariah
authors.initials: ZN
authors.lastname: Allaudin
authors.forename: Mohd-Azmi Mohd
authors.initials: MA
authors.lastname: Lila
mesh_terms: D004261:DNA Replication; D004274:DNA, Recombinant / Q000096:biosynthesis*; D004352:Drug Resistance, Microbial / Q000235:genetics; D005819:Genetic Markers; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D010957:Plasmids / Q000096:biosynthesis*; D014611:Vaccination; D019444:Vaccines, DNA / Q000096:biosynthesis*
chemical_list: D004274:DNA, Recombinant; D005819:Genetic Markers; D019444:Vaccines, DNA